Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN)
CUSIP: 92790C104
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.01 par value per share
- Shares outstanding
- 122,519,943
- Total 13F shares
- 94,556,649
- Share change
- +3,130,772
- Total reported value
- $1,321,909,936
- Put/Call ratio
- 528%
- Price per share
- $13.98
- Number of holders
- 169
- Value change
- +$44,977,645
- Number of buys
- 82
- Number of sells
- 92
Quarterly Holders Quick Answers
What is CUSIP 92790C104?
CUSIP 92790C104 identifies VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92790C104:
Top shareholders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
10%
|
12,222,986
|
$164,765,851 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
4.7%
|
5,708,110
|
$76,945,322 | — | 31 Mar 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
4.4%
|
5,380,449
|
$72,528,453 | — | 31 Mar 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
3.8%
|
4,700,000
|
$63,356,000 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.7%
|
4,563,100
|
$61,510,588 | — | 31 Mar 2025 | |
| VR Adviser, LLC |
13F
|
Company |
3.2%
|
3,882,709
|
$52,338,917 | — | 31 Mar 2025 | |
| Commodore Capital LP |
13F
|
Company |
2.9%
|
3,600,000
|
$48,528,000 | — | 31 Mar 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
4.5%
|
3,575,309
|
$48,373,931 | $0 | 31 Dec 2024 | |
| Fairmount Funds Management LLC |
13F
|
Company |
2.8%
|
3,445,813
|
$46,449,559 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.3%
|
2,865,500
|
$38,626,940 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.3%
|
2,792,925
|
$37,648,629 | — | 31 Mar 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,505,200
|
$31,609,200 | — | 23 Sep 2021 | |
| Novo Holdings A/S |
13F
|
Company |
1.8%
|
2,250,300
|
$30,334,044 | — | 31 Mar 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.7%
|
2,095,079
|
$28,241,665 | — | 31 Mar 2025 | |
| MAVERICK CAPITAL LTD |
13F
|
Company |
1.7%
|
2,061,274
|
$27,785,974 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.7%
|
2,021,619
|
$27,251,424 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
1,720,525
|
$23,197,317 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.4%
|
1,688,129
|
$22,757,000 | — | 31 Mar 2025 | |
| Eversept Partners, LP |
13F
|
Company |
1.1%
|
1,377,674
|
$18,571,046 | — | 31 Mar 2025 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
1.1%
|
1,370,356
|
$18,472,000 | — | 31 Mar 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1%
|
1,270,481
|
$17,126,084 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1%
|
1,248,721
|
$16,832,759 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1%
|
1,231,092
|
$16,595,120 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.91%
|
1,114,586
|
$15,024,619 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.88%
|
1,084,040
|
$14,612,860 | — | 31 Mar 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.87%
|
1,064,506
|
$14,349,541 | — | 31 Mar 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
0.8%
|
982,576
|
$13,245,124 | — | 31 Mar 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.72%
|
880,430
|
$11,868,196 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.66%
|
813,647
|
$10,967,962 | — | 31 Mar 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.61%
|
750,000
|
$10,110,000 | — | 31 Mar 2025 | |
| Jonathan Violin |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
720,110
mixed-class rows
|
$10,099,005 | — | 02 Feb 2023 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.6%
|
736,595
|
$9,929,301 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.57%
|
702,517
|
$9,469,929 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.54%
|
659,662
|
$8,892,244 | — | 31 Mar 2025 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.49%
|
595,000
|
$8,020,600 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.46%
|
565,963
|
$7,629,181 | — | 31 Mar 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.45%
|
552,850
|
$7,452,418 | — | 31 Mar 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.44%
|
537,024
|
$7,239,082 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.41%
|
504,185
|
$6,796,414 | — | 31 Mar 2025 | |
| Yiheng Capital Management, L.P. |
13F
|
Company |
0.41%
|
500,261
|
$6,743,518 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.4%
|
494,949
|
$6,671,912 | — | 31 Mar 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.37%
|
450,000
|
$6,066,000 | — | 31 Mar 2025 | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. |
13F
|
Company |
0.35%
|
423,272
|
$5,705,707 | — | 31 Mar 2025 | |
| Scott Dunseth Myers |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
259,500
|
$5,449,500 | — | 12 Apr 2023 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.32%
|
396,808
|
$5,348,972 | — | 31 Mar 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.32%
|
390,000
|
$5,257,200 | — | 31 Mar 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.3%
|
362,893
|
$4,891,798 | — | 31 Mar 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.29%
|
354,739
|
$4,781,882 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.28%
|
341,795
|
$4,607,398 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.26%
|
320,300
|
$4,317,644 | — | 31 Mar 2025 |
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) as of Q2 2025
As of 30 Jun 2025,
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) was held by
169 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
94,556,649 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., Deep Track Capital, LP, Commodore Capital LP, VANGUARD GROUP INC, Kynam Capital Management, LP, VR ADVISER, LLC, Fairmount Funds Management LLC, PRICE T ROWE ASSOCIATES INC /MD/, and TANG CAPITAL MANAGEMENT LLC.
This page lists
169
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
174
Q2 2025 holders
169
Holder diff
-5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.